155 related articles for article (PubMed ID: 37905183)
1. Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States.
Coleman RL; Garside J; Hurteau J; Nguyen J; Kobayashi M
J Health Econ Outcomes Res; 2023; 10(2):82-90. PubMed ID: 37905183
[No Abstract] [Full Text] [Related]
2. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L
Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294
[TBL] [Abstract][Full Text] [Related]
3. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France.
Roset M; Amonkar M; Patel R; Lara N; Kothari S
Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States.
Kelkar SS; Prabhu VS; Zhang J; Corman S; Macahilig C; Rusibamayila N; Odak S; Duska LR
Gynecol Oncol Rep; 2022 Aug; 42():101026. PubMed ID: 35800987
[TBL] [Abstract][Full Text] [Related]
5. Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.
Heffernan K; Nikitas FS; Shukla U; Camejo HS; Knott C
Gynecol Oncol; 2022 Aug; 166(2):317-325. PubMed ID: 35752507
[TBL] [Abstract][Full Text] [Related]
6. Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States.
Liu J; Emond B; Maiese EM; Lafeuille MH; Lefebvre P; Ghelerter I; Wu C; Hurteau JA; Thaker PH
Curr Med Res Opin; 2022 Nov; 38(11):1935-1945. PubMed ID: 35975577
[TBL] [Abstract][Full Text] [Related]
7. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.
Roncolato F; Lindemann K; Willson ML; Martyn J; Mileshkin L
Cochrane Database Syst Rev; 2019 Oct; 10(10):CD012160. PubMed ID: 31588998
[TBL] [Abstract][Full Text] [Related]
8. Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis.
Mevius A; Karl F; Wacker M; Welte R; Krenzer S; Link T; Maywald U; Wilke T
J Cancer Res Clin Oncol; 2023 May; 149(5):1929-1939. PubMed ID: 35840862
[TBL] [Abstract][Full Text] [Related]
9. Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
Tuninetti V; Pace L; Ghisoni E; Quarà V; Arezzo F; Palicelli A; Mandato VD; Geuna E; Cormio G; Biglia N; Borsotti L; Gallo S; Ferrero A; Jacomuzzi E; Fuso L; Pezua Sanjinez JOS; Puppo A; Caglio A; Rognone C; Turinetto M; Scotto G; Di Maio M; Valabrega G
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509300
[TBL] [Abstract][Full Text] [Related]
10. Healthcare Resource Utilization and Costs Among Commercially Insured Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States.
Kobayashi M; Garside J; Nguyen J
J Health Econ Outcomes Res; 2023; 10(2):104-110. PubMed ID: 37954059
[No Abstract] [Full Text] [Related]
11. Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer.
Amonkar MM; Chase M; Myer NM; Wang T; Turzhitsky V; Spira A
Cancer Treat Res Commun; 2023; 36():100712. PubMed ID: 37301728
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England.
Goulden S; Heffernan K; Sen Nikitas F; Shukla U; Knott C; Hunger M; Pahwa A; Schade R
Int J Gynecol Cancer; 2023 Nov; 33(11):1715-1723. PubMed ID: 37620100
[TBL] [Abstract][Full Text] [Related]
13. Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.
Colomba E; Alexandre J; Le Teuff G; Genestie C; Coupez D; Coquard IR; Brachet PE; de Percin S; Sajous C; Fabbro M; Delanoy N; Joly F; Frenel JS; Pautier P; Leary A
Gynecol Oncol; 2023 Feb; 169():78-84. PubMed ID: 36521352
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue "Diagnosis and Management of Endometrial Cancer".
Gadducci A; Cosio S
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944775
[TBL] [Abstract][Full Text] [Related]
15. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
[TBL] [Abstract][Full Text] [Related]
16. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
17. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain.
Garcia-Carbonero R; González Astorga B; Vidal Tocino R; Contreras Toledo D; Pericay C; Fernández Montes A; Falcó E; González Cordero M; Reina Zoilo JJ; Alonso V; Rodríguez Salas N; Gil-Raga M; Santos C; Páez D; Anton-Pascual B; Aguilar F; Morales P
Clin Transl Oncol; 2024 Apr; 26(4):864-871. PubMed ID: 37651021
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
[TBL] [Abstract][Full Text] [Related]
19. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
[No Abstract] [Full Text] [Related]
20. Understanding Characteristics, Treatment Patterns, and Clinical Outcomes for Individuals with Advanced or Recurrent Endometrial Cancer in Alberta, Canada: A Retrospective, Population-Based Cohort Study.
Martins D; O'Sullivan DE; Boyne DJ; Cheung WY; Allonby O; Habash M; Brenner DR; Riemer J; McGee J
Curr Oncol; 2023 Feb; 30(2):2277-2289. PubMed ID: 36826137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
